In Vivo Neuroregeneration
Leading A Revolution in Brain Repair

About Us

NeuExcell Therapeutics is an early stage biopharmaceutical company. We are developing a revolutionary brain repair technology for neurological diseases. Our mission is to cure neurodegenerative diseases and neural injuries, such as stroke, ALS, Huntington’s disease and Alzheimer’s disease, through our world-leading astrocyte-to-neuron transdifferentiation platform.

A Revolution in Brain Repair - In Situ Regeneration

Despite great investment and hope in the past decades, there is no effective therapy that can cure ALS or reverse the progression of Alzheimer's disease. Likewise, therapies that treat stroke or brain/spinal cord injury have limited and variable efficacy at the best. The fundamental problem that has not been adequately addressed is to recover a sufficient number of lost neurons to restore lost brain functions.

In neurodegenerative or acutely injured brains, neurons die while glial cells, a group of supporting cells surrounding neurons, become reactive and proliferate. Our in situ transdifferentiation technology takes the advantage of reactive and proliferative astrocytes, as a result of neuronal degeneration or injury, and converts these reactive glial cells into functional neurons with high efficiency. The newly generated neurons are fully functional and integrate into existing brain circuits, leading to functional recovery. This technology has a broad scope of applications to treat neurodegenerative diseases and neural injuries.

Our Team

Gong Chen, PhD

Board Chair and Founder

CEO, TBA

Xi Qin, MBA

Chief Financial Officer

Jie Xu

Chief Operating Officer

Qiang Lu, PhD

Board Director